Risk Factors Associated with Cortical Thickness and White Matter Hyperintensities in Dementia Free Okinawan Elderly

Lisa C. Silbert\(^a,b,\)\(^\ast\), David Lahna\(^a\), Nutta-on Promjunyakul\(^a\), Erin Boespflug\(^a\), Yusuke Ohyaa, Yasushi Higashiaesato\(^f\), Junko Nishihirac, Yuriko Katsumatad, Takashi Tokashikic and Hiroko H. Dodge\(^a,c\)

\(^a\)Department of Neurology, NIA-Layton Aging and Alzheimer’s Disease Center, Oregon Health & Science University, Portland, OR, USA
\(^b\)Portland Veterans Affairs Health Care System, Portland, OR, USA
\(^c\)Department of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus, Okinawa, Japan
\(^d\)Department of Biostatistics, University of Kentucky, Lexington KY, USA
\(^e\)Department of Neurology, Michigan Alzheimer’s Disease Center, University of Michigan, Ann Arbor, MI, USA
\(^f\)Department of Laboratory Medicine, University of the Ryukyus, Okinawa, Japan

Handling Associate Editor: Koji Abe

Accepted 31 January 2018

Abstract.

**Background:** Cortical gray matter (GM) and white matter (WM) deterioration are signals of neurodegeneration and increased dementia risk; however, their specific etiologies in dementia-free aging is unclear.

**Objective:** The objective of this study was to examine potentially modifiable risk factors of GM and WM degeneration in a well-characterized cohort of dementia-free elderly.

**Methods:** 96 Okinawan elderly participants (age 83.6) from the Keys to Optimal Cognitive Aging Project (KOCOA) underwent MRI and cognitive evaluation. Serum markers of inflammation (interleukin-6 (IL-6), high sensitivity C-reactive protein), cerebrovascular disease (systolic blood pressure (SBP) 140+, hemoglobin A1C (HgbA1C), total cholesterol), and essential minerals (copper (Cu), magnesium, and calcium) were examined in relation to mean cortical thickness (MCT) and white matter hyperintensities (WMH), adjusting for age and gender. Voxel-based morphometry (VBM) analyses identified relationships between regional GM density and the above markers.

**Results:** Decreased MCT was associated with SBP 140+ (\(p = 0.029\)) and increased serum IL-6 (\(p = 0.036\)), HgbA1C (\(p = 0.002\)), and Cu (\(p = 0.025\)). In VBM analyses, increased IL-6, HgbA1C, and Cu were associated with decreased GM density in temporal lobe regions. HgbA1C (\(p = 0.004\)) was associated with greater WMH volume.

**Conclusions:** Peripheral markers of Cu, CVD risk, and inflammation are associated with MRI-markers of decreased brain health in dementia-free Okinawan elderly, with regional cortical thinning in areas involved in early accumulation of Alzheimer’s disease pathology. Results identify potentially modifiable biomarkers as targets in the prevention of dementia in older individuals.

Keywords: Aging, Alzheimer’s disease, atrophy, brain, cerebrovascular disorders, cognitive aging, copper, inflammation, magnetic resonance imaging, micronutrients, vascular disease

\(^\ast\)Correspondence to: Lisa C. Silbert, MD, NIA – Layton Aging and Alzheimer’s Disease Center, Department of Neurology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, USA. Tel.: +1 503 494 6979; Fax: +1 503 494 7499; E-mail: silbertl@ohsu.edu.

ISSN 1387-2877/18/$35.00 © 2018 – IOS Press and the authors. All rights reserved

This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0).
INTRODUCTION

Changes in brain volume and structure have been associated with both increased age [1] and early neurodegeneration, particularly Alzheimer’s disease (AD) [2, 3], with brain atrophy being associated of AD pathology in an older population [4, 5]. Multiple risk factors have been associated with poorer brain health and include those associated with cerebrovascular disease (CVD), inflammation, and certain micronutrients. It is conceivable that early cortical injury in AD-vulnerable regions associated with chronic disease and lifestyle influences may decrease cognitive and neuronal reserve in older individuals, leaving them more susceptible to clinical manifestations of age and AD-related pathologies.

Cortical thickness measures can detect early brain change in older individuals, with regional decline in cortical thickness observed prior to the clinical onset of AD [6]. Furthermore, ante-mortem medial temporal lobe thickness has been related to in-vivo and post-mortem AD pathology markers [7]. In dementia-free elderly, preserved cortical thickness has been associated with superior cognitive performance [8], distinguishing “super agers” from those susceptible to the more commonly observed, age-related cognitive decline [9], supporting this use of cortical thickness as a strong biomarker of healthy aging.

T2-weighted MRI white matter hyperintensities (WMH) are an imaging hallmark of underlying small vessel ischemic disease [10]. WMHs are commonly observed in advanced age and confer increased risk of cognitive and motor impairment [11, 12], stroke, and overall mortality [13].

Recent studies have shown lifestyle factors, such as diet and exercise, to be associated with cortical thickness [14–16] and WMHs [17], indicating the likelihood that certain preventative measures may retard or delay cortical volume loss and WMH accumulation in the elderly. Individual serum biomarkers and specific risk factors related to structural brain change are not well established, and may lead to specific interventions aimed at improving cognitive health in our growing elderly population. Accordingly, the objective of this study was to examine peripheral markers and potentially modifiable risk factors associated with cortical thickness and WMHs in a well-characterized cohort of dementia-free Okinawan elderly.

MATERIALS AND METHODS

Subjects

96 dementia-free Okinawan participants from the Keys to Optimal Cognitive Aging Project (KOCOA), underwent detailed cognitive and neurological testing and MRI. The KOCOA project is a prospective pilot cohort study of community-dwelling elderly aged 80 years or older living in Ginowan City in Okinawa, Japan. The study was approved by the Ethics Committee and the Intuitional Review Board of the University of the Ryukyus. Informed consent was obtained from all participants prior to enrollment in the study. Details of the study recruitment and methods have been published elsewhere [18, 19]. In brief, subjects were recruited from those participating in one of 22 government-funded senior centers. A total of 196 volunteers (mean age: 85.2 years, range: 80–98) were followed annually, between November 2007 and March 2010, for a total of three time points. Cognitive function was evaluated by a trained examiner using the Japanese version of the 30-point Mini-Mental State Examination (JMMSE) [20, 21] as a measure of global cognitive function. 114/196 subjects had brain MRI corresponding to their baseline clinical evaluation. For the current study, we included those without frank dementia, defined as JMMSE > 20, Clinical Dementia Rating Scale (CDR) [22] score < 1.0, and without evidence of functional impairment on Instrumental Activities of Daily Living (IADL), including using the telephone, shopping, bill paying, preparing meals, and banking, leaving a total of 96 subjects included in this analysis. Eighty-five of these subjects had fluid attenuated inversion recovery (FLAIR) images for WMH analysis.

As part of their participation in the KOCOA study, all subjects had vital signs, including blood pressure, recorded at their baseline neurological and cognitive examination. Laboratory evaluation corresponding with their baseline visit examined markers of CVD risk and inflammation, as well as essential minerals previously shown to be associated with cerebrovascular or neurodegenerative disease. CVD risk markers included Hemoglobin A1C (HgbA1C), total cholesterol (Tchol), and systolic blood pressure $\geq 140$ (SBP 140+). Inflammatory markers included interleukin-6 (IL-6) and high sensitivity C-reactive protein (hsCRP). Nutrient biomarkers previously shown to be associated with brain health were obtained, and included magnesium (Mg), copper (Cu), and calcium (Ca) [23–25].
MRI acquisition and analysis

MRI was acquired on a Siemens 1.5T Avanto system, including T1 sequences: voxel size 0.9 × 0.9 × 1.25 mm³, 256 × 256 imaging matrix, 144 sagittal slices, TR: 1700 ms, TI: 800 ms, TE: 3.3 ms; FLAIR: 0.9 × 0.9 × 5 mm³, 19 axial slices, TR: 8500 ms, TI: 2500 ms, TE: 107 ms. Mean cortical thickness (MCT) was derived using FreeSurfer (version 5.1). Intracranial volume (ICV) was determined from a nonlinear registration to standard MNI space. WMH values were obtained using a semi-automated algorithm previously described [26]. Voxelwise GM density was calculated using the standard FSL VBM package (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLVBM). T1 images were brain extracted, non-linearly aligned to the MNI-152 template and GM extracted. These images were averaged to create a study-specific template to which all GM images were non-linearly aligned, modulated by the Jacobian and smoothed with an isotropic Gaussian kernel of sigma 2 mm. Cluster thresholded voxelwise GLM was used to explore the relationship between regional GM density and CVD risk factors and serum biomarkers of brain health described above (3dRegAna, AFNI).

Statistical analysis

Multivariable regression models, adjusted for age and sex, examined the relationships between MRI MCT and vascular disease (WMH) with peripheral vascular (HgbA1C, Tchol, SBP140+), inflammatory (IL-6, hsCRP) and nutrient (Cu, Mg, Ca) markers of brain health. WMH, hsCRP, and IL-6 were log transformed in order to obtain normal distribution. WMH volume was examined as a percentage of ICV to account for differences in head size. Whole brain VBM analyses examined relationships between regional GM density and factors found to be significant in the above MCT analyses. A final step-wise linear regression model was run, which included all variables previously found to be significant. Due to relatively small sample size in the current study, we used type I error rate of 0.05 as a statistical significance.

RESULTS

The mean age of participants was 83.6 (sd 3.0), with 76.6% women. Subject characteristics are described in Table 1. Multivariable analyses were adjusted for age and sex.

CVD risk markers

In individual multivariable analyses adjusted for age and sex, greater HgbA1C (p=0.002) and SBP 140+ (p=0.029) were associated with decreased MCT. Tchol was not associated with MCT. Of the CVD risk factors examined, only HgbA1C was related to greater WMH volume after adjustment for age and sex (p=0.0038) (Table 2).

Serum inflammatory markers

Decreased MCT was related to greater serum IL-6 (p=0.036) after adjustments for age and sex, but not with hsCRP. Neither of the serum inflammatory markers were related to WMH volume.

Table 1

| Subject characteristics (N = 96) | Mean (sd) | Range |
|---------------------------------|-----------|-------|
| Age (y)                         | 83.6 (3.0) | 78–92 |
| Sex (% women)                   | 76.6      |       |
| Education (y)                   | 7.8 (2.4)  | 0–17  |
| JMMSE                           | 26.2 (5.2) | 21–30 |
| CDR = 0 (%)                     | 71.4      |       |
| BMI                             | 24.3 (3.2) | 17–33.9 |
| WMH volume (cc, n = 85 with FLAIR) | 11.6 (10.4) | 0.59–61.1 |
| HgbA1C                          | 5.59 (0.66) | 4.5–8.1 |
| SBP > 140 (%)                   | 58.3      |       |
| Total cholesterol               | 211.18 (39.97) | 123–356 |
| Interleukin-6                   | 3.92 (7.56) | 0.9–74.2 |
| hsCRP                           | 0.29 (0.55) | 0.01–3.96 |
| Copper                          | 125.51 (20.56) | 67.1–191.2 |
| Magnesium                       | 2.36 (0.17) | 1.9–3.0 |
| Calcium                         | 9.52 (0.36) | 8.6–10.7 |

JMMSE, Japanese Mini-Mental State Exam; CDR, Clinical Dementia Rating; BMI, body mass index; WMH, white matter hyperintensity; HgbA1C, hemoglobin A1C; SBP, systolic blood pressure; hsCRP, high sensitivity C-reactive protein.

Table 2

| Results of multivariable linear regression analyses of CVD, Inflammatory, and Micronutrient factors related to structural brain health, age and sex adjusted (p<0.05) |
|---------------------------------|---------------------------------|---------------------------------|
| CVD RISK                        | MCT Estimate (p-value)          | WMH Estimate (p-value)          |
| HgbA1C                          | –0.08 (0.002)                   | 0.03 (0.038)                    |
| SBP > 140                       | –0.04 (0.029)                   | NS                              |
| Tchol                           | NS                              | NS                              |
| Inflammatory Markers            | –0.06 (0.036)                   | NS                              |
| IL-6                            | NS                              | NS                              |
| hsCRP                           | NS                              | NS                              |
| Micronutrients                  | Cu                              | –0.002 (0.025)                  | 0.001 (0.07)                    |
| Magnesium                       | NS                              | NS                              |
| Calcium                         | NS                              | NS                              |

CVD, cerebrovascular disease; HgbA1C, hemoglobin A1C; SBP, systolic blood pressure; Tchol, total cholesterol; IL-6, interleukin-6; hsCRP, high sensitivity C-reactive protein; Cu, copper.
Table 3
Regions in which VBM identified significantly reduced GM density in comparison with increased HgbA1c ($p < 0.05$)

| Talairach Region                      | Coordinates (X Y Z) | Cluster size (Voxels) | Volume (cm$^3$) |
|---------------------------------------|---------------------|-----------------------|-----------------|
| Middle Temporal Gyrus and Temporal Pole | R -52 10 -25        | 781                   | 6.25            |
| Lateral Occipital Cortex              | L 23 85 26          | 660                   | 5.28            |
| Superior Frontal Gyrus                | R -14 -20 55        | 470                   | 3.76            |

**Micronutrients**

Decreased MCT was associated with greater serum Cu ($p = 0.025$), but not with either Mg or Ca, after adjustments for age and gender. There was a weak relationship between higher serum Cu and greater WMH volume after adjustments for age and sex ($p = 0.07$). Mg and Ca were not related to MRI WMH burden.

**Final model of cortical thickness**

A mixed linear step-wise regression was performed composed of all variables previously shown to be associated with MCT, which included: HgbA1C, SBP 140+, Cu, and IL-6, adjusted for age and sex (probability to enter and leave, $p = 0.25$). All variables of interest remained in the model, with greater HgbA1C ($p = 0.001$), Cu ($p = 0.024$), and SBP 140+ ($p = 0.013$) remaining significantly related to decreased MCT, and IL-6 having attenuated its significance ($p = 0.092$).

**Voxel-based morphometry**

Voxel-wise analyses demonstrated that increased HgbA1C was associated with decreased GM density in the right middle temporal gyrus and temporal pole, left lateral occipital cortex, and right superior frontal gyri (Table 3, Fig. 1). Increased IL-6 was related to decreased GM density in the left inferior and middle temporal gyri (Table 4, Fig. 1). Greater serum Cu was related to more widespread cortical thinning, with regions of greatest impact being within medial frontal, medial temporal and parahippocampal structures (Table 5, Fig. 1). SBP 140+ was not related to regional GM thinning in VBM analysis.

**DISCUSSION**

Greater cortical thickness in older individuals has been associated with immunity from the typically observed decline in cognitive performance, separating “super agers” from those who have accelerated cortical thinning and poorer cognition commonly associated with aging [9]. These studies, and other investigations demonstrating lifestyle preferences and interventions to be associated with improvements in structural brain measures [14, 15], support the likely existence of modifiable targets associated with cortical thickness and cognitive health.

In this study, CVD risk factors of greater HgbA1c and SBP 140+ were associated with decreased MCT, with greater HgbA1c being associated with regional reductions of cortical density within the medial temporal lobe. Previous studies have found associations between CVD risk factors and brain atrophy [27], specifically in relation to blood glucose levels [28] and hypertension [29].

Diabetes is a known risk factor for cognitive impairment, including both vascular and Alzheimer’s dementias [30], with cognitive changes likely to occur in older individuals [30]. Like others, we found associations between diabetic risk and WMH burden [31, 32] implicating cerebrovascular disease as a significant contributor to cognitive impairment in diabetic elderly. It has been shown, however, that the risk for AD in diabetics remains strong even after controlling for CVD risk factors, supporting shared molecular pathways between AD and diabetes, including greater neuronal insulin resistance, amyloid-β (Aβ) aggregation, tau hyperphosphorylation, and reduced Aβ clearance [30, 33], all of which might be possible contributors to early cortical changes.

HTN is also a strong risk factor for vascular dementia [34] with likely mediation via associations with arteriolosclerosis, endothelial dysfunction, and subsequent small vessel ischemic disease. In this study of older, non-demented, Okinawan participants, SBP 140+ was not associated with MRI WMH burden, indicating detrimental effects of chronic hypertension on brain health that are independent of the effects associated with typical CVD. Previous studies have demonstrated associations between HTN and cortical thickness, possibly due, in part, to decrease cortical perfusion resulting from impaired autoregulatory cerebrovascular response [29, 35]. Finally, both greater blood glucose and SBP increase the risk for cortical microinfarcts [30, 36], further explaining possible associations between these CVD risk factors and cortical thickness measures.

An equitable balance between pro- and anti-inflammatory responses is thought to separate older individuals experiencing longevity and successful
Fig. 1. VBM analysis with cluster thresholding to account for false positive rates. Colored voxels indicate regions of decreased GM density significantly associated with higher HgbA1C (a), Copper (b), and IL-6 (c), age and sex adjusted ($p < 0.05$).

Table 4

| Talairach Region | Coordinates | Cluster size |
|------------------|-------------|-------------|
|                  | X   | Y   | Z   | Voxels | Volume (cm$^3$) |
| Inferior and Middle Temporal Gyrus | L 56 | 11 | -30 | 698 | 5.58 |

Table 5

| Talairach Region | Coordinates | Cluster size |
|------------------|-------------|-------------|
|                  | X   | Y   | Z   | Voxels | Volume (cm$^3$) |
| Middle Frontal Gyrus | L+ R 3 | -37 | 46 | 565 | 4.52 |
| Parahippocampal Gyrus | R -25 | 11 | -30 | 561 | 4.49 |
| Middle Temporal Gyrus | R -57 | 26 | -9 | 519 | 4.15 |
| Parahippocampal Gyrus | L 23 | 12 | -29 | 506 | 4.05 |
| Intracalcarine Cortex | L 50 | 70 | 3 | 456 | 3.65 |
| Lateral Occipital Cortex | R -46 | 65 | 40 | 437 | 3.5 |
| Temporal Pole | R -57 | -2 | 27 | 427 | 3.42 |

Aging from those more susceptible to increased morbidity, and decreased survival [37]. IL-6 is a pro-inflammatory cytokine produced by both immune and non-immune cells, including adipocytes, which contribute up to 35% of circulating IL-6 levels [38]. Previous studies have reported associations between IL-6 and chronic disease of aging, including those related to impaired cognitive function [39, 40], even after controlling for vascular risk factors [41]. Findings from this study are consistent with others showing associations between IL-6 and structural brain changes [42–44]. Few studies have
examined IL-6 in relation to cortical thickness specifically. Our findings are consistent with one previous study of older individuals demonstrating relationships between IL-6 and both cross-sectional and longitudinal cortical thinning that included temporal lobe structures [42]. We did not observe a relationship between hsCRP and cortical thickness in this study. Previous investigations examining brain volume change with CRP have demonstrated conflicting results, with some reporting significant correlations with regional GM volume [45], and others finding either no relationship [46] or weaker relationships compared with that observed between brain structure and IL-6 [43, 44]. In the present study, neither CRP nor IL-6 were related to WMH, findings similar to many previous reports [43, 46–48], with a few exceptions [44, 49].

This study is one of the first to examine circulating Cu levels in relation to human brain structure, showing regional effects of Cu on medial temporal lobe structures known to be involved in early accumulation of AD pathology. In animal models fed a high cholesterol diet, even low doses of dietary Cu have been shown to result in accumulation of Aβ and worse cognitive performance [50, 51]. Recent investigations have demonstrated Cu to accumulate within the brain capillaries of older mice, thought to cause disruption of Aβ clearance across the blood-brain barrier through its down-regulation of endothelial low-density lipoprotein receptor-related protein 1 (LRP1), with additional effects on Aβ production and neuroinflammation in transgenic mice overexpressing Aβ precursor protein [52, 53]. In humans, the overall effects of Cu appear mixed, with dietary and serum Cu levels associated with decreased blood pressure and cholesterol, but higher markers of peripheral inflammation, oxidative stress [54], and HgbA1C [55] and with increased risk for conversion from MCI to AD [25]. Importantly, we found greater Cu levels to be related to MCT in the final model adjusted for IL-6 and HgbA1C, indicating its effects to be independent of these secondary inflammatory and blood glucose/insulin resistance markers. It is possible, however, that the relationship between serum Cu and cortical thinning was driven by other inflammatory or oxidative stress markers previously associated with serum Cu, but not explicitly examined in this study. Interestingly, a weak association between serum Cu and WMH burden was observed in this population. Previous studies have demonstrated a role of Cu in the development of atherosclerotic disease through the generation of reactive oxygen species. It is likely that this relationship is biphasic, with both Cu deficiency and excess Cu causing enhanced atherogenesis, although the argument has been made that even “normal” levels of Cu may contribute to atherosclerotic disease in older individuals (for a review, see [56]). This is one of the first studies to investigate the relationship between MRI WMH and serum Cu levels in an elderly population, and findings may indicate a more important role for Cu in age-related cerebrovascular dysfunction than previously recognized. Future examination of the effects of Cu on GM and WM integrity in other cohorts will be necessary to fully elucidate these relationships.

This study has several limitations, including the lack of longitudinal MRI to investigate risk factors for rates of cortical thinning and detailed dietary and medication information on study participants. In addition, inflammatory markers examined in this study were peripheral, and direct effect on the CNS can only be surmised. A direct link between peripheral and central inflammation is biologically plausible, however, with possible pathways including active passage across the blood-brain barrier and passive diffusion from the choroid plexus (see Rosano [57] for review). Future studies investigating peripheral in relation to central inflammatory markers (i.e., using novel PET ligands) will be necessary to validate these relationships.

In this study of highly characterized, dementia-free, Okinawan elderly, MCT was associated with SBP 140+ and greater serum HgbA1C, IL-6, and Cu, with specific regional effects observed within the temporal lobe, an area known to be susceptible to the accumulation of AD pathology prior to clinical manifestation of dementia. In addition, greater HgbA1C and to a lesser extent, serum Cu, were related to greater CVD burden. The identified peripheral markers and risk factors predictive of worse brain structure are all potentially modifiable, and thus represent specific targets for prevention and intervention therapies aimed at maintaining brain health and increasing resistance to age and neurodegenerative disease-related decline in cognitive function in older individuals.

ACKNOWLEDGMENTS

This study was supported by the National Institute on Aging (K01AG023014, R01AG033581, P30AG008017); Linus Pauling Institute Research Grant, Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) Grant-
in-Aid for Young Scientists (B) (20790442), JSPS KAKENHI Grant Number 23591278 and JSPS KAKENHI Grant Number 26461313.

Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/17-1153r1).

REFERENCES

[1] Salat DH, Buckner RL, Snyder AZ, Greve DN, Desikan RS, Busa E, Morris JC, Dale AM, Fischl B (2004) Thinning of the cerebral cortex in aging. Cereb Cortex 14, 721-730.

[2] Whitwell JL, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, Petersen RC, Jack Jr CR (2007) 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer’s disease. Brain 130, 1777-1786.

[3] Dodge HH, Zhu J, Harvey D, Saito N, Silbert LC, Kaye JA, Koepp RA, Albin RL, Alzheimer’s Disease Neuroimaging Initiative (2014) Biomarker transitions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease. Alzheimers Dement 10, 690-703.

[4] Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G, Sexton G, Kaye JA (2003) Changes in premorbid brain volume predict Alzheimer’s disease pathology. Neurology 61, 487-492.

[5] Kaur B, Himmel JJ, Seshadri S, Beiser AS, Au R, McKee AC, Auerbach S, Wolf PA, DeCarli CS (2014) Association between neuropathology and brain volume in the Framingham Heart Study. Alzheimers Dis Assoc Disord 28, 219-225.

[6] Pettigrew C, Soldan A, Zhu Y, Wang MC, Moghekar A, Brown T, Miller M, Albert M, BIOCARD Research Team (2016) Cortical thickness in relation to clinical symptom onset in preclinical AD. Neuroimage Clin 12, 116-122.

[7] LaPoint MR, Chhatwal JP, Sepulcre J, Johnson KA, Sperling RA, Schultz AP (2017) The association between tau PET and retrospective cortical thinning in clinically normal elderly. Neuroimage 157, 612-622.

[8] Dickerson BC, Fenstermacher E, Whitwell JL, Przybelski SA, Wolk DA, Maguire RP, Desikan R, Pacheco J, Quinn BT, Van der Kooi A, Greve DN, Blacker D, Albert MS, Killiany RJ, Fischl B (2008) Detection of cortical thickness correlates of cognitive performance: Reliability across MRI scan sessions, scanners, and field strengths. Neuroimage 39, 10-18.

[9] Rogalski EJ, Gelen T, Shi J, Samimi M, Bigio E, Weintraub S, Geula C, Mesulam MM (2013) Youthful memory capacity in old brains: Anatomic and genetic clues from the Northwestern SuperAging Project. J Cogn Neurosci 25, 29-36.

[10] Etten-Lyons D, Woltjer R, Kaye J, Mattek N, Dodge HH, Green S, Tran H, Howieson DB, Wild K, Silbert LC (2013) Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology 81, 977-983.

[11] Silbert LC, Nelson C, Howieson DB, Moore MM, Kaye JA (2008) Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline. Neurology 71, 108-113.

[12] Silbert LC, Dodge HH, Perkins LG, Sherbakov L, Lahna D, Etten-Lyons D, Woltjer R, Shinto L, Kaye JA (2012) Trajectory of white matter hyperintensity burden preceding mild cognitive impairment. Neurology 79, 741-747.

[13] DeBette S, Markus HS (2010) The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: Systematic review and meta-analysis. BMJ 341, c3666.

[14] Reiter K, Nielson KA, Smith TJ, Weiss LR, Alfini AJ, Smith JC (2015) Improved cardiorespiratory fitness is associated with increased cortical thickness in mild cognitive impairment. J Int Neuropsychol Soc 21, 757-767.

[15] Lee JS, Shin HY, Kim HJ, Jang YK, Jung NY, Lee J, Kim YJ, Chun P, Yang JJ, Lee JM, Kang M, Park KC, Na DL, Seo SW (2016) Combined effects of physical exercise and education on age-related cortical thinning in cognitively normal individuals at risk for Alzheimer’s disease. J Prev Alzheimers Dis 1, 23-32.

[16] Mosconi L, Murray TS, McHugh PR (2017) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.

[17] Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. [see comment]. Neurology 43, 2412-2414.

[18] Ozawa M, Ninomiya T, Ohara T, Hirakawa Y, Doi Y, Hata J, Uchida K, Shirato T, Kitazono T, Kiyohara Y (2012) Self-reported dietary intake of potassium, calcium, and magnesium and risk of dementia in the Japanese: The Hisayama Study. J Am Geriatr Soc 54, 1500-1515.

[19] Squitti R, Barbati G, Rossi L, Ventriglia M, Dal Forno G, Cesaretti S, Moffa F, Cardi I, Cassetta E, Pasqualetti P, Calabrese L, Lupoi D, Rossini PM (2006) Excess of non-ceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau. Neurology 67, 76-82.

[20] Squitti R, Ghidoni R, Sirotti M, Ventriglia M, Benussi L, Paterlini A, Magri M, Binetti G, Cassetta E, Caparra D, Vernieri F, Rossini PM, Pasqualetti P (2014) Value of serum nonceruloplasmin copper for prediction of mild cognitive impairment conversion to Alzheimer disease. Ann Neurol 75, 574-580.

[21] Promjunyakul N, Lahna D, Kaye JA, Etten-Lyons D, Rooney WD, Silbert LC (2015) Characterizing the white matter hyperintensity penumbra with cerebral blood flow measures. Neuroimage Clin 8, 224-229.

[22] Tchistiaieva E, MacIntosh BJ, Alzheimer’s Disease Neuroimaging Initiative (2016) Summative effects of vascular risk factors on cortical thickness in mild cognitive impairment. Neurobiol Aging 45, 98-106.
[28] Wennberg AM, Spira AP, Pettigrew C, Soldan A, Zipan-
nikov V, Rebok GW, Roses AD, Lutz MW, Miller MM, Tham-
bsietty M, Albert MS (2016) Blood glucose levels and
cortical thinning in cognitively normal, middle-aged adults.
*J Neurol Sci* 365, 89-95.

[29] Aloso ML, Gunstad J, Xu X, Clark US, Labbe DR, Riskin-
Jones HH, Terrero G, Schwarz NF, Walsh EG, Poppas A,
Cohen RA, Sweet LH (2014) The impact of hypertension
on cerebral perfusion and cortical thickness in older adults.
*J Am Soc Hypertens* 8, 561-570.

[30] J SR-F, Sa-Rozit TM, Rosset I, Camozzato AL, San-
tos AC, Chaves ML, Moriguti JC, Rozit-Cruz M (2009)
(Prediabetes, brain aging, and cognition. *Biochim Biophys
Acta* 1792, 432-443.

[31] Rozanszki R, Richter TB, Gotts U, Endres M, Fiebach JB,
Junghulsing GJ (2014) Elevated levels of hemoglobin A1c
are associated with cerebral white matter disease in patients
with stroke. *Stroke* 45, 1007-1011.

[32] Gouw AA, van der Flier WM, Fazekas F, van Straaten EC,
Pantoni L, Poggesi A, Inzitari D, Erkinjuntti T, Wablund
LO, Waldemar G, Schmidt R, Scheltens P, Barkhof F, Group
LS (2008) Progression of white matter hyperintensities
and incidence of new lacunes over a 3-year period: The
Leukoaraisis and Disability study. *Stroke* 39, 1414-1420.

[33] Zhao WQ, Townsend M (2009) Insulin resistance and amy-
lloidogenesis as common molecular foundation for type 2
diabetes and Alzheimer’s disease. *Biochim Biophys Acta*
1792, 482-496.

[34] Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y,
Mayeux R (2002) The relationship of hypertension in the
erly aged to AD, vascular dementia, and cognitive function.
*Neurology* 58, 1175-1181.

[35] Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings
MI, SMART Study Group (2012) Hypertension and longi-
tudinal changes in cerebral blood flow: The SMART-MR
study. *Ann Neurol* 71, 825-833.

[36] Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick
Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings
MI, SMART Study Group (2012) Hypertension and longi-
tudinal changes in cerebral blood flow: The SMART-MR
study. *Ann Neurol* 71, 825-833.

[37] Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick
Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings
MI, SMART Study Group (2012) Hypertension and longi-
tudinal changes in cerebral blood flow: The SMART-MR
study. *Ann Neurol* 71, 825-833.

[38] Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick
Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings
MI, SMART Study Group (2012) Hypertension and longi-
tudinal changes in cerebral blood flow: The SMART-MR
study. *Ann Neurol* 71, 825-833.

[39] Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick
Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings
MI, SMART Study Group (2012) Hypertension and longi-
tudinal changes in cerebral blood flow: The SMART-MR
study. *Ann Neurol* 71, 825-833.

[40] Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick
Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings
MI, SMART Study Group (2012) Hypertension and longi-
tudinal changes in cerebral blood flow: The SMART-MR
study. *Ann Neurol* 71, 825-833.

[41] Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick
Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings
MI, SMART Study Group (2012) Hypertension and longi-
tudinal changes in cerebral blood flow: The SMART-MR
study. *Ann Neurol* 71, 825-833.

[42] Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick
Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings
MI, SMART Study Group (2012) Hypertension and longi-
tudinal changes in cerebral blood flow: The SMART-MR
study. *Ann Neurol* 71, 825-833.

[43] Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick
Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings
MI, SMART Study Group (2012) Hypertension and longi-
tudinal changes in cerebral blood flow: The SMART-MR
study. *Ann Neurol* 71, 825-833.

[44] Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick
Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings
MI, SMART Study Group (2012) Hypertension and longi-
tudinal changes in cerebral blood flow: The SMART-MR
study. *Ann Neurol* 71, 825-833.

[45] Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick
Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings
MI, SMART Study Group (2012) Hypertension and longi-
tudinal changes in cerebral blood flow: The SMART-MR
study. *Ann Neurol* 71, 825-833.

[46] Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick
Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings
MI, SMART Study Group (2012) Hypertension and longi-
tudinal changes in cerebral blood flow: The SMART-MR
study. *Ann Neurol* 71, 825-833.

[47] Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick
Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings
MI, SMART Study Group (2012) Hypertension and longi-
tudinal changes in cerebral blood flow: The SMART-MR
study. *Ann Neurol* 71, 825-833.